--- title: "Tinavi spent 15 years on one orthopedic robot — and became China's surgical-robot pioneer" date: 2026-09-28 category: Humanoids & Robotics site: NeuroAI canonical: https://neuroai.site/a/na-robot-tinavi-surgical language: en --- # Tinavi spent 15 years on one orthopedic robot — and became China's surgical-robot pioneer > Tinavi's TiRobot (天玑) has assisted in more than 180,000 orthopedic procedures and made the company China's first listed surgical-robot maker. The hard part now is turning surgical volume into profit and a real business beyond the machine itself. Most surgical robots are famous for one number: the price tag. Tinavi's TiRobot is better measured by a different one — the procedures it has quietly stacked up across Chinese hospitals while the company lost money the whole time. ## A robot born in a research lab Tinavi (天智航) traces its orthopedic-robot program to 2005 and was incorporated in Beijing in 2010, led by founder-chairman Zhang Songgen (张送根). The goal was narrow and stubborn: build a robot that could plan and guide orthopedic implants — screws, plates, joint replacements — with accuracy a freehand surgeon cannot match. The result is TiRobot (天玑), which Tinavi says is the first product worldwide to cover spine, trauma and joint-replacement surgery on a single platform. Instead of replacing the surgeon, it locks the planned trajectory and holds it during drilling and insertion, cutting radiation exposure from repeated fluoroscopy. ## From first listing to 180,000 procedures In July 2020 Tinavi listed on Shanghai's STAR Market (688277) as "the surgical-robot first stock" — the first Chinese listed company built mainly around surgical robots. Fifteen years of engineering had produced something rarer than a prototype: installed, used machines. By early 2026 Tinavi said TiRobot had passed 160,000 cumulative procedures; by mid-2026 the company cited more than 180,000. In 2025 alone the robot performed over 49,000 surgeries, up from about 39,000 in 2024. It now sits in more than 200 medical institutions across 31 provincial-level regions, and Tinavi says it has done over 1,000 remote robotic surgeries since 2006, reaching county hospitals in places like Yan'an and Lhasa. ## A leader that still loses money Being first did not make Tinavi profitable. Revenue reached 278.8 million yuan (≈ US$39M / HK$305M) in 2025, up 55.9% from 178.8 million yuan in 2024, and it held the number-one share of China's orthopedic surgical-robot market — above 40%. Yet the company posted a net loss of 183 million yuan (≈ US$26M), wider than 2024, as it spent to grow. The structure is the problem. Robot hardware still drives most revenue; the sticky, recurring income from implants and service is small. That is why, in July 2026, Tinavi disclosed a plan to acquire 62% of Shanghai MicroPort Orthopedics (上海微创骨科), a move to pair its robot with the implants and overseas channels a full orthopedic business needs. In August 2026 it also obtained a registration certificate for orthopedic surgical-planning software. ## Why volume is the moat For a surgical robot, usage is the real metric. Each procedure trains surgeons, locks in a hospital, and generates the service and consumable revenue that eventually pays back the losses. Tinavi's edge is that it has the longest clinical track record in China — 300-plus patents, 20-plus national research projects, and roughly 40% of staff in R&D. The risk is that track record does not yet convert to cash. New reimbursement policies for robot-assisted surgery, rolling out province by province in 2026, are the swing factor: if hospitals get paid for the procedure, demand for the machine follows. ## What readers can do now - **If you evaluate hospital tech**, ask for annual procedure volume per installed robot, not the number of robots sold — that ratio separates showpieces from working systems. - **If you follow Chinese medtech**, watch the robot-surgery fee policies in Guangdong and Hunan as the commercial on-switch for the whole category. - **If you invest**, read Tinavi's implant-and-service share of revenue as the signal that "robot + implant" can become a business, not just a loss-making flagship. ## Honest limitations Founding and product facts (program from 2005, incorporated 2010 Beijing, founder-chairman Zhang Songgen, TiRobot as single-platform spine/trauma/joint robot, 300+ patents, 20+ research projects, ~40% R&D staff, 200+ institutions, 31 regions, 1,000+ remote surgeries since 2006) come from Tinavi's official site and investor materials. STAR Market listing July 2020 (688277), "surgical-robot first stock," 2025 revenue 278.8M yuan (+55.9%), 2024 revenue 178.8M yuan, 2025 net loss 183M yuan (wider than 2024), >40% market share, 2025 ~49k / 2024 ~39k / 2026 Q1 >160k and mid-2026 >180k cumulative procedures come from Tinavi filings and 界面新闻 (Jiemian) / 新浪财经 reporting. The July 2026 plan to buy 62% of Shanghai MicroPort Orthopedics and the August 2026 surgical-planning software registration are from company disclosures via 百度百科 and 新浪财经. Procedure and revenue figures are company-reported and not independently audited here; the mid-2026 >180k cumulative count is the company's latest stated figure and may be revised. RMB converted at ~7.1/US$ and 0.915/US$ for HK$. Not investment advice. --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-robot-tinavi-surgical Free to quote with attribution and a link to the original.